What’s Trending?

Think tank Reform has warned that the National Health Service risks losing out on huge potential revenue in the future if it does not put in place a strategy to capitalise on the increasing value of its medical data. [...]
Mon, Dec 10, 2018
Source PharmaTimes
Gilead Sciences has announced that Daniel O'Day, the current CEO of Roche's pharmaceutical unit, will become their chief executive effective from March 1 next year. Daniel will replace current CEO John Milligan, after Gilead revealed that John will step down at the end of 2018. [...]
Mon, Dec 10, 2018
Source PharmaTimes
A new clinical study has found that Kaia Health's artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD). [...]
Mon, Dec 10, 2018
Source PharmaTimes
Roche's Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland. [...]
Mon, Dec 10, 2018
Source PharmaTimes
FDA
Today, the U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase retention (the amount of time a patient participates) in an outpatient treatment program for individuals with opioid use disorder (OUD). The reSET-O app is a prescription cognitive behavioral therapy intended to be used in [...]
Mon, Dec 10, 2018
Source WorldPharmaNews
Connecticut Assistant Attorney General Joseph Nielsen told The Washington Post that the generic drug market is possibly the biggest "cartel" in U.S. history. And investigators are looking to prove it by expanding their probe of potential collusion among generics makers to 300 drugs—up from just two at the outset. [...]
Mon, Dec 10, 2018
Source FiercePharma
Akorn once again tried and failed to salvage its $4.3 billion merger with Fresenius. Delaware's top court ruled that Fresenius had nixed the deal legally after data problems cropped up, and in the wake of the decision, Akorn's CEO made his exit. [...]
Mon, Dec 10, 2018
Source FiercePharma
AstraZeneca
AstraZeneca today announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. The Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, [...]
Mon, Dec 10, 2018
Source WorldPharmaNews
With Gilead Sciences' CEO on the way out and hep C revenues tumbling, the company needs a leader who can pump up in oncology. And hoping to find just that, it has poached a top executive from the biggest cancer drugmaker in the world. [...]
Sun, Dec 09, 2018
Source FiercePharma
Cannes Lions Health last week named the two jury chiefs set to oversee the advertising awards in health & wellness and pharma for 2019, the sixth year for the creative healthcare advertising showcase. [...]
Sun, Dec 09, 2018
Source FiercePharma
The venom of insects such as wasps and bees is full of compounds that can kill bacteria. Unfortunately, many of these compounds are also toxic for humans, making it impossible to use them as antibiotic drugs. After performing a systematic study of the antimicrobial properties of a toxin normally found [...]
Fri, Dec 07, 2018
Source WorldPharmaNews
Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung [...]
Thu, Dec 06, 2018
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews